FRE Shares Firebrick Pharma Limited
ASX · ASXLast in our picks 2026-10-09 — not in the current list; analysis below is from that screen
Emerging-market marketplace portfolio offers high growth and substantial operating leverage if profitability improves.
Future value: $0.05 (+72.41%) · 6-12 months
Signal breakdown
- ▸Portfolio monetization potential but thin liquidity.
- ▸Above 50-day MA (+0.62%)
- ▸Volume 4.42× average — accumulation
- ▾Near 52-week low (10% of range)
- ▸~72% upside to price target
Is FRE a buy right now?
Trend: FRE is trading above the 50-day average (+3.33%), RSI 30 — neutral momentum, with a 3-month return of +19.23%.
Valuation & quality: Firebrick Pharma Limited trades on price-to-book 5.17; fundamentals show net margin 0.0%, return on equity -189.2%, revenue growth -86.4% year on year.
Our screen: BUY (score 3) — Emerging-market marketplace portfolio offers high growth and substantial operating leverage if profitability improves.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +20.00% | -16.70% | -20.00% | +0.00% | -25.00% | +33.30% | -25.00% | +0.00% |
Fundamentals
Technical signals
About Firebrick Pharma Limited
Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Sector: Healthcare · Industry: Drug Manufacturers - General · Australia · Website
Related Communication Services picks
Browse: all ASX stocks · Communication Services picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.